Prolyl hydroxylase and hypoxia inducible factor: potential targets for cancer therapy

References

• Bornstein, P. The biosynthesis of collagen. Annu. Rev. Biochem. 1974, 43, 567–603.
   PubMed Web of Science ®Google Scholar
• Grant, M.E., Prockop, D.J. The biosynthesis of collagen. 1. N. Engl. J. Med. 1972, 286, 194–199.
   PubMed Web of Science ®Google Scholar
• Grant, M.E., Prockop, D.J. The biosynthesis of collagen. 2. N. Engl. J. Med. 1972, 286, 242–249.
   PubMed Web of Science ®Google Scholar
• Takeuchi, T., Kivirikko, K.I., Prockop, D.J. Increased protocollagen hydroxylase activity in the livers of rats with hepatic fibrosis. Biochem. Biophys. Res. Commun. 1967, 28, 940–944.
   PubMed Web of Science ®Google Scholar
• Stein, H.D., Keiser, H.R., Sjoerdsma, A. Proline-hydroxylase activity in human blood. Lancet 1970, 1, 106–109.
   PubMed Web of Science ®Google Scholar
• Keiser, H.R., Vogel, C.L., Sadikali, F. Protocollagen proline hydroxylase in sera of Ugandans with hepatocellular carcinoma. J. Natl. Cancer Inst. 1972, 49, 1251–1255.
   PubMedGoogle Scholar
• Tug, S., Delos Reyes, B., Fandrey, J., Berchner-Pfannschmidt, U. Non-hypoxic activation of the negative regulatory feedback loop of prolyl-hydroxylase oxygen sensors. Biochem. Biophys. Res. Commun. 2009, 384, 519–523.
   PubMed Web of Science ®Google Scholar
• Couvelard, A., Deschamps, L., Rebours, V., Sauvanet, A., Gatter, K., Pezzella, F., Ruszniewski, P., Bedossa, P. Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin. Cancer Res. 2008, 14, 6634–6639.
   PubMed Web of Science ®Google Scholar
• McGee, J.O., O Hare, R.P., Patrick, R.S. Stimulation of the collagen biosynthetic pathway by factors isolated from experimentally-injured liver. Nat. New Biol. 1973, 243, 121–123.
   PubMedGoogle Scholar
• Chan, D.A., Kawahara, T.L., Sutphin, P.D., Chang, H.Y., Chi, J.T., Giaccia, A.J. Tumor vasculature is regulated by PHD-2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009, 15, 527–538.
   PubMed Web of Science ®Google Scholar
• Myllyharju, J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr. Pharm. Des. 2009, 15, 3878–3885.
   PubMed Web of Science ®Google Scholar
• Maynard, M.A., Qi, H., Chung, J., Lee, E. H., Kondo, Y., Hara S., Conaway, R.C., Conaway, J.W., Ohh, M. Multiple splice variants of the human HIF-3alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem 2003, 278, 11032–11040.
   PubMed Web of Science ®Google Scholar
• Schofield, C.J., Ratcliffe, P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5, 343–354.
   PubMed Web of Science ®Google Scholar
• Rankin, E.B., Rha, J., Selak, M.A., Unger, T.L., Keith, B., Liu, Q., Haase, V.H. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 2009, 29, 4527–4538.
   PubMed Web of Science ®Google Scholar
• Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D., Pouysségur, J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003, 22, 4082–4090.
   PubMed Web of Science ®Google Scholar
• Appelhoff, R.J., Tian, Y.M., Raval, R.R., Turley, H., Harris, A.L., Pugh, C.W., Ratcliffe, P.J., Gleadle, J.M. Differential function of the prolyl hydroxylases PHD-1, PHD-2, and PHD-3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 2004, 279, 38458–38465.
   PubMed Web of Science ®Google Scholar
• Semenza, G.L., Jiang, B.H., Leung, S.W., Passantino, R., Concordet, J.P., Maire, P., Giallongo, A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271, 32529–32537.
   PubMed Web of Science ®Google Scholar
• Boulahbel, H., Durán, R.V., Gottlieb, E. Prolyl hydroxylases as regulators of cell metabolism. Biochem. Soc. Trans. 2009, 37, 291–294.
   PubMed Web of Science ®Google Scholar
• Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.M., Lanahan, A.A., Pollard, P., Ruiz de Almodovar, C., De Smet, F., Vinckier, S., Aragonés, J., Debackere, K., Luttun, A., Wyns, S., Jordan, B., Pisacane, A., Gallez, B., Lampugnani, M.G., Dejana, E., Simons, M., Ratcliffe, P., Maxwell, P., Carmeliet, P. Heterozygous deficiency of PHD-2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136, 839–851.
   PubMed Web of Science ®Google Scholar
• Rankin, E.B., Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15, 678–685.
   PubMed Web of Science ®Google Scholar
• Lee, K.A., Lynd, J.D., O’Reilly, S., Kiupel, M., McCormick, J.J., LaPres, J.J. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD-2, in modulating tumor-forming potential. Mol. Cancer Res. 2008, 6, 829–842.
   PubMed Web of Science ®Google Scholar
• Cioffi, C.L., Liu, X.Q., Kosinski, P.A., Garay, M., Bowen, B.R. Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem. Biophys. Res. Commun. 2003, 303, 947–953.
   PubMed Web of Science ®Google Scholar
• Ozer, A., Bruick, R.K. Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING-4. Cell Cycle 2005, 4, 1153–1156.
   PubMed Web of Science ®Google Scholar
• Semenza, G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007, 12, 853–859.
   PubMed Web of Science ®Google Scholar
• Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D., Buechler, P., Isaacs, W.B., Semenza, G.L., Simons, J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59, 5830–5835.
   PubMed Web of Science ®Google Scholar
• Ziello, J.E., Jovin, I.S., Huang, Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007, 80, 51–60.
   PubMedGoogle Scholar
• Höckel, M., Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266–276.
   PubMed Web of Science ®Google Scholar
• Vaupel, P., Kelleher, D.K., Höckel, M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 2001, 28, 29–35.
   PubMed Web of Science ®Google Scholar
• Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9 Suppl 5, 10–17.
   PubMed Web of Science ®Google Scholar
• Moulder, J.E., Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987, 5, 313–341.
   PubMed Web of Science ®Google Scholar
• Durand, R.E. Keynote address: the influence of microenvironmental factors on the activity of radiation and drugs. Int. J. Radiat. Oncol. Biol. Phys. 1991, 20, 253–258.
   PubMed Web of Science ®Google Scholar
• Giaccia, A.J. Hypoxic stress proteins: survival of the fittest. Semin. Radiat. Oncol. 1996, 6, 46–58.
   PubMed Web of Science ®Google Scholar
• Riva, C., Chauvin, C., Pison, C., Leverve, X. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res. 1998, 18, 4729–4736.
   PubMed Web of Science ®Google Scholar
• Haroon, Z.A., Raleigh, J.A., Greenberg, C.S., Dewhirst, M.W. Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann. Surg. 2000, 231, 137–147.
   PubMed Web of Science ®Google Scholar
• Vaupel, P., Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9 Suppl 5, 4–9.
   PubMed Web of Science ®Google Scholar
• Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., Semenza, G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 1138–1143.
   PubMed Web of Science ®Google Scholar
• Koong, A.C., Denko, N.C., Hudson, K.M., Schindler, C., Swiersz, L., Koch, C., Evans, S., Ibrahim, H., Le, Q.T., Terris, D.J., Giaccia, A.J. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60, 883–887.
   PubMed Web of Science ®Google Scholar
• Czekay, R.P., Aertgeerts, K., Curriden, S.A., Loskutoff, D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 2003, 160, 781–791.
   PubMed Web of Science ®Google Scholar
• Harris, A.L. Hypoxia — a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38–47.
   PubMed Web of Science ®Google Scholar
• Brown, J.M., Giaccia, A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408–1416.
   PubMed Web of Science ®Google Scholar
• Prabhakar, N.R. Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J. Appl. Physiol. 2001, 90, 1986–1994.
   PubMed Web of Science ®Google Scholar
• Shi, Y.H., Fang, W.G. Hypoxia-inducible factor-1 in tumour angiogenesis. World J. Gastroenterol. 2004, 10, 1082–1087.
   PubMed Web of Science ®Google Scholar
• Vaupel, P., Kallinowski, F., Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49, 6449–6465.
   PubMed Web of Science ®Google Scholar
• Bos, R., Zhong, H., Hanrahan, C.F., Mommers, E.C., Semenza, G.L., Pinedo, H.M., Abeloff, M.D., Simons, J.W., van Diest, P.J., van der Wall, E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 2001, 93, 309–314.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K.C., Harris, A.L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 2001, 85, 881–890.
   PubMed Web of Science ®Google Scholar
• Berra, E., Ginouvès, A., Pouysségur, J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 2006, 7, 41–45.
   PubMed Web of Science ®Google Scholar
• Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K.I., Myllyharju, J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 2003, 278, 30772–30780.
   PubMed Web of Science ®Google Scholar
• Michaela, G., Celeste, S.M. Hypoxia inducible factor, hypoxia and tumour angiogenesis. Curr. Opin. Hematol. 2006, 13, 169–174.
   PubMed Web of Science ®Google Scholar
• Maxwell, P.H., Ratcliffe, P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 2002, 13, 29–37.
   PubMed Web of Science ®Google Scholar
• Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I., Dang, C.V., Semenza, G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of c-Myc activity. Cancer Cell 2007, 11, 407–420.
   PubMed Web of Science ®Google Scholar
• Déry, M.A., Michaud, M.D., Richard, D.E. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol. 2005, 37, 535–540.
   PubMed Web of Science ®Google Scholar
• Vincent, K.A., Shyu, K.G., Luo, Y., Magner, M., Tio, R.A., Jiang, C., Goldberg, M.A., Akita, G.Y., Gregory, R.J., Isner, J.M. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000, 102, 2255–2261.
   PubMed Web of Science ®Google Scholar
• Trentin, D., Hall, H., Wechsler, S., Hubbell, J.A. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc. Natl. Acad. Sci. USA. 2006, 103, 2506–2511.
   PubMed Web of Science ®Google Scholar
• Toi, M., Hoshina, S., Takayanagi, T., Tominaga, T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 1994, 85, 1045–1049.
   PubMedGoogle Scholar
• Maeda, K., Chung, Y.S., Ogawa, Y., Takatsuka, S., Kang, S.M., Ogawa, M., Sawada, T., Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858–863.
   PubMed Web of Science ®Google Scholar
• Bochner, B.H., Cote, R.J., Weidner, N., Groshen, S., Chen, S.C., Skinner, D.G., Nichols, P.W. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. 1995, 87, 1603–1612.
   PubMed Web of Science ®Google Scholar
• Jaeger, T.M., Weidner, N., Chew, K., Moore, D.H., Kerschmann, R.L., Waldman, F.M., Carroll, P.R. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol. 1995, 154, 69–71.
   PubMed Web of Science ®Google Scholar
• Zhang, W., Tsuchiya, T., Yasukochi, Y. Transitional change in interaction between HIF-1 and HNF-4 in response to hypoxia. J. Hum. Genet. 1999, 44, 293–299.
   PubMed Web of Science ®Google Scholar
• Bos, R., Van Diest, P.J., van, der, Groep, P., Shvarts, A., Greijer, A.E., van der Wall, E. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast. Cancer. Res. 2004, 6, 450–459.
   Web of Science ®Google Scholar
• Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C., Semenza, G.L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 2001, 21, 3995–4004.
   PubMed Web of Science ®Google Scholar
• Yen, L., Benlimame, N., Nie, Z.R., Xiao, D., Wang, T., Al Moustafa, A.E., Esumi, H., Milanini, J., Hynes, N.E., Pages, G., Alaoui-Jamali, M.A. Differential regulation of tumor angiogenesis by distinct ErbB homo-and heterodimers. Mol. Biol. Cell 2002, 13, 4029–4044.
   PubMed Web of Science ®Google Scholar
• Dales, J.P., Garcia, S., Meunier-Carpentier, S., Andrac-Meyer, L., Haddad, O., Lavaut, M.N., Allasia, C., Bonnier, P., Charpin, C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005, 116, 734–739.
   PubMed Web of Science ®Google Scholar
• Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B., Kerbel, R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997, 151, 1523–1530.
   PubMed Web of Science ®Google Scholar
• Gruber, G., Greiner, R.H., Hlushchuk, R., Aebersold, D.M., Altermatt, H.J., Berclaz, G., Djonov, V. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast. Cancer. Res. 2004, 6, 191–198.
   Web of Science ®Google Scholar
• Zhong, H., Semenza, G.L., Simons, J.W., De Marzo, A.M. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 2004, 28, 88–93.
   PubMedGoogle Scholar
• Kimbro, K.S., Simons, J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 2006, 13, 739–749.
   PubMed Web of Science ®Google Scholar
• Du, Z., Fujiyama, C., Chen, Y., Masaki, Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin. Med. J. 2003, 116, 1936–1939.
   PubMed Web of Science ®Google Scholar
• Mabjeesh, N.J., Willard, M.T., Frederickson, C.E., Zhong, H., Simons, J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 2003, 9, 2416–2425.
   PubMed Web of Science ®Google Scholar
• Sheflin, L.G., Zou, A.P., Spaulding, S.W. Androgens regulate the binding of endogenous HuR to the AU-rich 3′ UTRs of HIF-1alpha and EGF mRNA. Biochem. Biophys. Res. Commun. 2004, 322, 644–651.
   PubMed Web of Science ®Google Scholar
• Koong, A.C., Chen, E.Y., Giaccia, A.J. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 1994, 54, 1425–1430.
   PubMed Web of Science ®Google Scholar
• Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Harris, A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000, 157, 411–421.
   PubMed Web of Science ®Google Scholar
• Leek, R.D., Talks, K.L., Pezzella, F., Turley, H., Campo, L., Brown, N.S., Bicknell, R., Taylor, M., Gatter, K.C., Harris, A.L. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 2002, 62, 1326–1329.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki, A., Sivridis, E., Fiska, A., Koukourakis, M.I. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl. Immunohistochem. Mol. Morphol. 2006, 14, 78–82.
   PubMedGoogle Scholar
• Onita, T., Ji, P.G., Xuan, J.W., Sakai, H., Kanetake, H., Maxwell, P.H., Fong, G.H., Gabril, M.Y., Moussa, M., Chin, J.L. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin. Cancer Res. 2002, 8, 471–480.
   PubMed Web of Science ®Google Scholar
• Ji, P., Xuan, J.W., Onita, T., Sakai, H., Kanetake, H., Gabril, M.Y., Sun, Y., Moussa, M., Chin, J.L. Correlation study showing no concordance between EPAS-1/HIF-2alpha mRNA and protein expression in transitional cellcancer of the bladder. Urology 2003, 61, 851–857.
   PubMed Web of Science ®Google Scholar
• Yoshimura, H., Dhar, D.K., Kohno, H., Kubota, H., Fujii, T., Ueda, S., Kinugasa, S., Tachibana, M., Nagasue, N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 2004, 10, 8554–8560.
   PubMed Web of Science ®Google Scholar
• Koukourakis, M.I., Bentzen, S.M., Giatromanolaki, A., Wilson, G.D., Daley, F.M., Saunders, M.I., Dische, S., Sivridis, E., Harris, A.L. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 2006, 24, 727–735.
   PubMed Web of Science ®Google Scholar
• Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., Kaelin, W.G.Jr, . Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1, 237–246.
   PubMed Web of Science ®Google Scholar
• Knowles H, Leek R, Harris AL. Macrophage infiltration and angiogenesis in human malignancy. Novartis. Found. Symp. 2004, 256, 189–200; discussion 200–204, 259–269.
   PubMedGoogle Scholar
• Kondo, K., Kim, W.Y., Lechpammer, M., Kaelin, W.G.Jr, . Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003, 1, E83.
   PubMed Web of Science ®Google Scholar
• Jiang, B.H., Rue, E., Wang, G.L., Roe, R., Semenza, G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271, 17771–17778.
   PubMed Web of Science ®Google Scholar
• Dioum, E.M., Chen, R., Alexander, M.S., Zhang, Q., Hogg, R.T., Gerard, R.D., Garcia, J.A. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009, 324, 1289–1293.
   PubMed Web of Science ®Google Scholar
• Kaelin, W.G.Jr, . Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2002, 2, 673–682.
   PubMed Web of Science ®Google Scholar
• Covello, K.L., Simon, M.C., Keith, B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 2005, 65, 2277–2286.
   PubMed Web of Science ®Google Scholar
• Holmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, A., Gradin, K., Poellinger, L., Påhlman, S. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10, 413–423.
   PubMed Web of Science ®Google Scholar
• Covello, K.L., Kehler, J., Yu, H., Gordan, J.D., Arsham, A.M., Hu, C.J., Labosky, P.A., Simon, M.C., Keith, B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20, 557–570.
   PubMed Web of Science ®Google Scholar
• Hoehner, J.C., Gestblom, C., Hedborg, F., Sandstedt, B., Olsen, L., Påhlman, S. A developmental model of neuroblastoma: differentiating stroma-poor tumors’ progress along an extra-adrenal chromaffin lineage. Lab. Invest. 1996, 75, 659–675.
   PubMed Web of Science ®Google Scholar
• Le Douarin, N., Smith, J. Development of the peripheral nervous system from the neural crest. Annu. Rev. Cell. Biol. 1998, 4, 375–404.
   Google Scholar
• Ghafar, M.A., Anastasiadis, A.G., Chen, M.W., Burchardt, M., Olsson, L.E., Xie, H., Benson, M.C., Buttyan, R. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 2003, 54, 58–67.
   PubMed Web of Science ®Google Scholar
• Löfstedt, T., Fredlund, E., Holmquist-Mengelbier, L., Pietras, A., Ovenberger, M., Poellinger, L., Påhlman, S. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007, 6, 919–926.
   PubMed Web of Science ®Google Scholar
• Erez, N., Milyavsky, M., Eilam, R., Shats, I., Goldfinger, N., Rotter, V. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 2003, 63, 8777–8783.
   PubMed Web of Science ®Google Scholar
• Fox, S.B., Bragança, J., Turley, H., Campo, L., Han, C., Gatter, K.C., Bhattacharya, S., Harris, A.L. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Res. 2004, 64, 6075–6081.
   PubMed Web of Science ®Google Scholar
• Knowles, H.J., Raval, R.R., Harris, A.L., Ratcliffe, P.J. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003, 63, 1764–1768.
   PubMed Web of Science ®Google Scholar
• Lee, K., Qian, D.Z., Rey, S., Wei, H., Liu, J.O., Semenza, G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. USA. 2009, 106, 2353–2358.
   PubMed Web of Science ®Google Scholar
• Hewitson, K.S., Schofield, C.J. The HIF pathway as a therapeutic target. Drug Discov. Today 2004, 9, 704–711.
   PubMed Web of Science ®Google Scholar
• Jones, M.K., Szabó, I.L., Kawanaka, H., Husain, S.S., Tarnawski, A.S. von Hippel-Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J. 2002, 16, 264–266.
   PubMedGoogle Scholar
• Gordan, J.D., Lal, P., Dondeti, V.R., Letrero, R., Parekh, K.N., Oquendo, C.E., Greenberg, R.A., Flaherty, K.T., Rathmell, W.K., Keith, B., Simon, M.C., Nathanson, K.L. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-clear cell renal carcinoma. Cancer Cell 2008, 14, 435–446.
   PubMed Web of Science ®Google Scholar
• Wiedmann, M.W., Caca, K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 2005, 5, 171–193.
   PubMed Web of Science ®Google Scholar
• Tan, C., de Noronha, R.G., Roecker, A.J., Pyrzynska, B., Khwaja, F., Zhang, Z., Zhang, H., Teng, Q., Nicholson, A.C., Giannakakou, P., Zhou, W., Olson, J.J., Pereira, M.M., Nicolaou, K.C., Van Meir, E.G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65, 605–612.
   PubMed Web of Science ®Google Scholar
• Luwor, R.B., Lu, Y., Li, X., Mendelsohn, J., Fan, Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005, 24, 4433–4441.
   PubMed Web of Science ®Google Scholar
• Mabjeesh, N.J., Escuin, D., LaVallee, T.M., Pribluda, V.S., Swartz, G.M., Johnson, M.S., Willard, M.T., Zhong, H., Simons, J.W., Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3, 363–375.
   PubMed Web of Science ®Google Scholar
• Burkitt, K., Chun, S.Y., Dang, D.T., Dang, L.H. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol. Cancer. Ther. 2009, 8, 1148–1156.
   PubMed Web of Science ®Google Scholar
• Nilsson, M.B., Zage, P.E., Zeng, L., Xu, L., Cascone, T., Wu, H.K., Saigal, B., Zweidler-McKay, P.A., Heymach, J.V. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for anti-angiogenic mechanisms of multikinase inhibitors. Oncogene 2010, 29, 2938–2949.
   PubMed Web of Science ®Google Scholar
• Prabhu, V., Guruvayoorappan, C. Nitric oxide: pros and cons in tumor progression. Immunopharmacol. Immunotoxicol. 2010, 32, 387–392.
   PubMed Web of Science ®Google Scholar
• Fang, J., Zhou, Q., Liu, L.Z., Xia, C., Hu, X., Shi, X., Jiang, B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007, 4, 58–64.
   Google Scholar
• Choi, H., Chun, Y.S., Kim, S.W., Kim, M.S., Park, J.W. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 2006, 70, 1664–1671.
   PubMed Web of Science ®Google Scholar
• Nagle, D.G., Zhou, Y.D. Marine natural products as inhibitors of hypoxic signaling in tumors. Phytochem. Rev. 2009, 8, 415–429.
   PubMed Web of Science ®Google Scholar
• Jin, W., Cai, X.F., Na, M., Lee, J.J., Bae, K. Triterpenoids and diarylheptanoids from Alnus hirsuta inhibit HIF-1 in AGS cells. Arch. Pharm. Res. 2007, 30, 412–418.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Morgan, J.B., Coothankandaswamy, V., Liu, R., Jekabsons, M.B., Mahdi, F., Nagle, D.G., Zhou, Y.D. The Caulerpa pigment caulerpin inhibits HIF-1 activation and mitochondrial respiration. J. Nat. Prod. 2009, 72, 2104–2109.
   PubMed Web of Science ®Google Scholar
• Schofield, C.J., Ratcliffe, P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5, 343–354.
   PubMed Web of Science ®Google Scholar